Home | Login | Subscribe Today!Nov. 20, 2009
 New Drugs

Click here to Subscribe Today!
New Drugs Approved by the FDA in 2009

More info and advice about the most significant newly approved drugs is available each month for members of Pharmacist's Letter. If you're not already a member, Subscribe Today!

New Molecular Entities/Significant Biologicals - 2009
 Brand/Generic  Company  Description
Afinitor
everolimus
Novartis An oral kinase inhibitor for advanced kidney cancer.


Arzerra
ofatumumab
GSK A monoclonal antibody for chronic lymphocytic leukemia (CLL).


ATryn
antithrombin
Ovation Pharm. An anticoagulant for patients with hereditary antithrombin deficiency.


Bepreve
bepotastime
Ista Pharms An ophthalmic antihistamine for allergic conjunctivitis.


Berinert
C1 Esterase Inhibitor
CSL Behring GmbH A C1 esterase inhibitor (human) for hereditary angioedema.


Besivance
besifloxacin
Bausch & Lomb An ophthalmic suspension for bacterial conjunctivitis.


Cervarix
human papillomavirus
GSK A vaccine to prevent cervical pre-cancers/cancer caused by human papillomavirus types 16 & 18.


Coartem
artemether/lumefantrine
Novartis Combination product for treatment of acute, uncomplicated malaria infections.


Dysport
abobotulinumtoxin A
Ipsen Biopharm A botulinum toxin for cervical dystonia and improvement of facial lines.


Effient
prasugrel
Lilly/Daiichi Sankyo An antiplatelet for use in patients who undergo angioplasty.


Extavia
interferon beta-1b
Novartis An interferon beta for treatment of relapsing forms of multiple sclerosis.


Fanapt
iloperidone
Vanda Pharm. An atypical antipsychotic for schizophrenia.


Folotyn
pralatrexate
Allos Therapeutics A folate analogue metabolic inhibitor for peripheral T-cell lymphoma.


Hiberix
haemophilus influenzae b (Hib) vaccine
GSK A Hib booster dose for children 15 months through 4 years old.


Ilaris
canakinumab
Novartis An interleukin-1 blocker for Cryopyrin-Associated Periodic Syndromes.


Istodax
romidepsin
Gloucester Pharm. A histone deacetylase inhibitor for cutaneous T-cell lymphoma.


Ixiaro
Japanese encephalitis vaccine
Intercell Biomedical A vaccine for prevention of Japanese encephalitis.


Livalo
pitavastatin
Kowa Pharm. An HMG Co-A reductase inhibitor to reduce cholesterol levels.


Multaq
dronedarone
Sanofi-Aventis An antiarrhythmic for atrial fibrillation or atrial flutter.


Onglyza
saxagliptin
BMS/AstraZeneca A DPP-4 inhibitor for control of blood sugar in adults with type 2 diabetes.


RiaSTAP
fibrinogen concentrate (human)
CSL Behring An intravenous fibrinogen product to treat bleeding in patients with congenital fibrinogen deficiency.


Sabril
vigabatrin
Lundbeck An antiepileptic drug for complex partial seizures in adults (tablets) and infantile spasms (oral solution) in children.


Samsca
tolvaptan
Otsuka Pharm. A vasopressin V2-receptor antagonist for treatment of hyponatremia.


Saphris
asenapine
Schering-Plough An atypical antipsychotic for acute treatment of schizophrenia and bipolar I.


Savella
milnacipran
Forest Labs An SNRI for management of fibromyalgia.


Simponi
golimumab
Centocor Ortho Biotech A TNF-alpha blocker for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.


Stelara
ustekinumab
Centocor Ortho Biotech A monoclonal antibody for moderate to severe psoriasis.


Ulesfia
benzyl alcohol
Sciele Pharma A 5% lotion for topical treatment of head lice.


Uloric
febuxostat
Takeda A xanthine oxidase inhibitor for chronic management of gout.


Vibativ
telavancin
Theravance Inc. A lipoglycopeptide antibiotic for complicated gram-positive skin infections.


Votrient
pazopanib
GSK A kinase inhibitor for advanced renal cell carcinoma.


Return to top
Significant New Dosage Forms - 2009
 Brand/Generic  Company  Description
Adcirca
tadalafil
Lilly New formulation for pulmonary arterial hypertension.


Astepro
azelastine
Meda Pharms New 0.15% nasal spray for seasonal and perennial allergic rhinitis.


Caldolor
ibuprofen
Cumberland Pharm. Injectable formulation for treatment of pain and fever.


Cambia
diclofenac
Kowa Pharm. Oral solution for acute treatment of migraine attacks.


Colcrys
colchicine
Mutual Pharma First FDA-approved formulation of colchicine.


Cycloset
bromocriptine
VeroScience LLC New 0.8 mg tablets for management of type 2 diabetes.


Edluar
zolpidem
Orexo AB Sublingual formulation for insomnia.


Embeda
morphine/naltrexone
King Pharma. Analgesic for around-the-clock management of moderate to severe pain.


Feraheme
ferumoxytol
Amag Pharms Intravenous iron replacement for anemia of chronic kidney disease.


Gelnique
oxybutynin
Watson Topical gel for treatment of overactive bladder.


Intuniv
guanfacine
Shire New extended-release tablets for treatment of ADHD.


Invega Sustenna
paliperidone
Janssen Once-monthly injectable formulation for acute/maintenance treatment of schizophrenia.


Kapidex
dexlansoprazole
Takeda The R-enantiomer of lansoprazole for erosive esophagitis and heartburn associated with non-erosive GERD.


Lamictal ODT
lamotrigine
GSK New orally disintegrating tablets (ODT).


Lamictal XR
lamotrigine
GSK Extended-release formulation for partial onset seizures.


Lipsovir
acyclovir/hydrocortisone
Medivir Topical cream for early treatment of recurrent cold sores.


Metozolv ODT
metoclopramide
Salix Orally disintegrating tablets for symptoms associated with diabetic gastroparesis and short-term treatment of GERD.


Onsolis
fentanyl
Meda Pharm. New buccal soluble film formulation for breakthrough cancer pain.


Pennsaid
diclofenac
Covidien New topical NSAID solution for osteoarthritis of the knee.


Plan B One-Step
levonorgestrel
Duramed New single dose emergency contraceptive.


Prevacid 24HR
lansoprazole
Novartis Over-the-counter PPI for treatment of heartburn.


Sumavel DosePro
sumatriptan
Zogenix New needle-free subcutaneous delivery system for acute treatment of migraines and cluster headaches.


Synvisc-One
hylan G-F 20
Genzyme New single-injection formulation for osteoarthritis of the knee.


Temodar
temozolomide
Schering New intravenous formulation for glioblastoma and anaplastic astrocytoma.


Twynsta
telmisartan/amlodipine
Boehringer Ingelheim New ARB and calcium channel blocker combination for treatment of hypertension.


Tyvaso
treprostinil
United Therap Inhalation formulation for treatment of pulmonary arterial hypertension.


Valturna
aliskiren/valsartan
Novartis New combination direct renin inhibitor plus ARB for hypertension.


Vectical
calcitriol
Galderma Labs Topical ointment for treatment of plaque psoriasis.


Zipsor
diclofenac
Xanodyne Pharm New liquid filled capsule formulation for mild to moderate acute pain.


Zirgan
ganciclovir
Sirion Therapeutics Ophthalmic gel for acute herpetic keratitis (dendritic ulcers).


Return to top
Drug Withdrawals - 2009
 Brand/Generic  Company  Description
Raptiva
efalizumab
Genentech Voluntary, phased withdrawal (by June 8, 2009) from the market due to potential risk of progressive multifocal leukoencephalopathy (PML).



Return to top
Click here to Subscribe Today!
Subscribe to Pharmacist's Letter Today
Holiday Gifts!
Pharmacist's Letter CE LIVE
Pharmacist’s Letter eLetter
 
Home | Search or Browse | Index of Topics | Privacy Policy | Email Us
Therapeutic Research Center
3120 W. March Lane, PO Box 8190, Stockton, CA 95208, Tel:(209) 472-2240 Fax:(209) 472-2249
Copyright © 1995-2009, All rights reserved.